阿德福韦酯联合拉米夫定治疗HBeAg阳性慢性乙型肝炎患者的临床疗效及安全性研究

目的研究阿德福韦酯联合拉米夫定治疗HBeAg阳性慢性乙型肝炎患者的临床疗效及安全性。方法：随机选取HBeAg阳性慢性乙型肝炎患者112例，分为两组，即阿德福韦酯联合拉米夫定治疗组（联合治疗组，n=56）和阿德福韦酯单独治疗组（单独治疗组。n=56），对两组患者的ALT复常、HBVDNA和HBeAg阴转情况及药物不良反应发生隋况进行统计分析。结果：联合治疗组治疗后36周的ALT复常率96．4％，显著高于单独治疗组的78．6％（P〈0．05），治疗后24周、36周的HBVDNA阴转率均显著高于单独治疗组（P〈0．05）：治疗后48周的BeAg阴转率28．6％，显著高于单独治疗组17．996（P〈0．05）。结论：阿德福韦酯联合拉米夫定治疗HBeAg阳性慢性乙型肝炎患者的临床疗效显著，安全性高。

Objective To study the clinical efficacy and safety of adefovir combined with lamivudine in the treatment of patients with HBeAg-positive chronic hepatitis B.Methods：112 cases of HBeAg positive chronic hepatitis B patients were randomly selected and divided into two groups, namely adafovir dipivoxil combined with lamivudine in the treatment group （combined treatment group,n=56） and adefovir dipivoxil treatment alone group （alone in the treatment group,n=56）,alanine aminotransferase （ALT） of two groups of patients recovery, HBV DNA and HBeAg negative conversion rate and drug adverse reaction incidence were statistically analyzed. Results：the combined treatment after 36 weeks of ALT complex often rate of 96.4%, significantly higher than alone therapy group 78.6% （P〈0.05）, 24 and 36 weeks after treatment of HBV DNA negative conversion rate were significantly higher than those of alone in the treatment group （P〈0.05）; 48 weeks after treatment of BEAG negative conversion rate was 28.6%, significantly higher than that of monotherapy versus 17.9% （P〈0.05）.Canclusion：The clinical efficacy of adefovir with lamivudine in the treatment of patients with HBeAg-positlve chronic hepatitis B is significant, the safety is high.